Truvestments Capital LLC purchased a new stake in Sanofi SA (NYSE:SNY) in the 1st quarter, HoldingsChannel reports. The fund purchased 1,115 shares of the company’s stock, valued at approximately $49,000.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Bessemer Group Inc. increased its stake in Sanofi by 11.8% in the 4th quarter. Bessemer Group Inc. now owns 2,409 shares of the company’s stock valued at $104,000 after buying an additional 255 shares during the period. Focused Wealth Management Inc grew its stake in Sanofi by 33.2% in the 4th quarter. Focused Wealth Management Inc now owns 1,204 shares of the company’s stock valued at $52,000 after acquiring an additional 300 shares during the last quarter. Investors Research Corp grew its stake in Sanofi by 1.0% in the 4th quarter. Investors Research Corp now owns 30,340 shares of the company’s stock valued at $1,317,000 after acquiring an additional 300 shares during the last quarter. Visionary Asset Management Inc. grew its stake in Sanofi by 2.8% in the 4th quarter. Visionary Asset Management Inc. now owns 11,342 shares of the company’s stock valued at $492,000 after acquiring an additional 314 shares during the last quarter. Finally, CENTRAL TRUST Co grew its stake in Sanofi by 7.7% in the 4th quarter. CENTRAL TRUST Co now owns 4,925 shares of the company’s stock valued at $213,000 after acquiring an additional 350 shares during the last quarter. 7.04% of the stock is currently owned by institutional investors.
SNY has been the topic of a number of research reports. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $48.00 price objective on the stock in a research note on Monday, February 4th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research note on Monday, January 14th. TheStreet cut shares of Sanofi from a “b” rating to a “c+” rating in a research note on Thursday, February 7th. Finally, HC Wainwright reissued a “buy” rating on shares of Sanofi in a research note on Thursday, February 28th. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $51.00.
NYSE:SNY opened at $42.63 on Tuesday. The stock has a market capitalization of $106.87 billion, a price-to-earnings ratio of 13.62, a PEG ratio of 2.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. Sanofi SA has a 12-month low of $37.43 and a 12-month high of $45.62.
Sanofi (NYSE:SNY) last released its earnings results on Thursday, February 7th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.01. The company had revenue of $9 billion for the quarter, compared to analyst estimates of $9 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.06 EPS. Analysts forecast that Sanofi SA will post 3.1 earnings per share for the current year.
The company also recently announced an annual dividend, which will be paid on Friday, May 31st. Shareholders of record on Wednesday, May 8th will be issued a $1.7395 dividend. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a yield of 4.2%. Sanofi’s dividend payout ratio (DPR) is 38.34%.
In other Sanofi news, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.00% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Truvestments Capital LLC Purchases Shares of 1,115 Sanofi SA (SNY)” was posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://macondaily.com/2019/04/16/truvestments-capital-llc-purchases-shares-of-1115-sanofi-sa-sny.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: How to execute a trade ex-dividend strategy?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.